Probi AB
STO:PROB

Watchlist Manager
Probi AB Logo
Probi AB
STO:PROB
Watchlist
Price: 251 SEK -5.28% Market Closed
Market Cap: 2.9B SEK
Have any thoughts about
Probi AB?
Write Note

P/E
Price to Earnings

208.7
Current
53.5
Median
23
Industry
Higher than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
208.7
=
Market Cap
2.9B SEK
/
Net Income
13.7m SEK
All Countries
Close
Market Cap P/E
SE
Probi AB
STO:PROB
2.9B SEK 208.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -178 533.6
US
Abbvie Inc
NYSE:ABBV
300.2B USD 59.1
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 37.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.8B USD -264.2
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD 912.5
US
Epizyme Inc
F:EPE
94.1B EUR -478.6
AU
CSL Ltd
ASX:CSL
137.3B AUD 33.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.3B USD 19
US
Seagen Inc
F:SGT
39.3B EUR -55.4
NL
argenx SE
XBRU:ARGX
34.1B EUR -129.9
Earnings Growth
SE
Probi AB
STO:PROB
Average P/E: 211.8
208.7
190%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59.1
412%
US
Amgen Inc
NASDAQ:AMGN
37.5
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -264.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
912.5
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
67.9
2-Years Forward
P/E
44.1
3-Years Forward
P/E
58.6

See Also

Discover More